7/04 National Cancer Insitute Communication:
"District Judge Issues Permanent Injunction Against Lane Labs-USA, Inc. and Orders Firm to Refund Money to Purchasers of Illegally Marketed Unapproved Drugs (7/13/04)
The Food and Drug Administration announced that Judge William G. Bassler of the United States District Court for the District of New Jersey, has found that three products sold by Lane Labs-USA, Inc. and its president Andrew J. Lane (the defendants) as dietary supplements and a cosmetic - Benefin, MGN-3 and SkinAnswer - are, in fact, unapproved new drugs under federal law because they were being marketed as treatments for cancer, HIV, and skin cancer without FDA approval.
In addition, Judge Bassler permanently enjoined the defendants from distributing BeneFin, MGN-3, and SkinAnswer unless the products are first either approved for marketing by FDA or distributed pursuant to an Investigational New Drug (IND) application for purposes of conducting a clinical trial.
Judge Bassler also ordered the defendants to pay restitution to all purchasers of BeneFin, MGN-3, and SkinAnswer since September 22, 1999.
NOTE THIS ACTION, is this product similar to SkinAnswer?:
FDA Approves New Use of Drug to Treat Superficial Basal Cell Carcinoma, a Type of Skin Cancer (7/15/04)
The Food and Drug Administration (FDA) announced the approval of a new indication for Aldara (imiquimod) topical cream. This product is currently approved for the treatment of actinic keratosis and external genital warts. Today, FDA is approving its use for the treatment of superficial basal cell carcinoma (sBCC), a type of skin cancer.
This type of skin cancer is diagnosed by a healthcare provider after biopsy and is different from other types of skin cancer including other types of basal cell carcinoma. Superficial basal cell carcinoma is usually treated by surgical removal. Aldara should be used for treatment of sBCC only when surgery is medically less appropriate, because the chances of effectively treating sBCC are generally greater with surgery. Patients treated with Aldara for sBCC should have regular follow-up visits after treatment to make sure the skin cancer is completely treated. http://www.fda.gov/bbs/topics/news/2004/NEW01088.html
Triple T-cell, B-cell & NK-cell Protection
MGN-3 is a processed rice bran polysaccharide that has a powerful immunomodulation effect. MGN-3 (Arabinoxylane compound) is a polysacharide dietary fiber formula from rice bran (hemicellulose B) that has been enzymatically modified by carbohydrates complex from mushroom. Major component is Arabinoxylane.
Main ingredients: 100% Rice Bran, enzymatically treated with extract from Shitake mushroom (Lentinus Edodes), Kawaratake (Coriolus Versicolor), Suehirotake (Schizophyllum Commune).
Other ingredients: Beet Root Fiber, Calcium Phosphate, Silica, Magnesium Stearate.
MGN-3 is a hemicellulose complex containing arabinoxylane as a major component, which is produced by hydrolyzing rice bran using multiple enzymes from mycelia of edible mushrooms.
It is less hygroscopic and is easily soluble in water. Arabinoxylane is obtained from enzyme reaction under constant condition and is highly active and stable.
Enhances the activity of white blood cells known as natural killer (NK) cells which are considered to be the first line of defense against cancer.
Improves immunocompetence to prevent cancer. NOTE: Seems to enhance the activty of NK (Natural Killer)cells.
Combined use with chemotherapy and hormone therapy alleviates side effects of drugs and improves QOL (Quality of Life)
Prevents leucopenia caused by chemotherapy and radiotherapy, and minimizes suppression of their efficacies.
Promotes leukocyte growth (3 times higher than control group)
Enhances activity of T cells.
Increases Interferon-Gamma production.
For maintenance of health: 600mg/day.
UCLA/DREW University, Department of Urology of Nippon
Medical School, Kobe Women College, Jichi Medical School,
Kyorin University, Hokkaido University, Teikyo University.
NOTE: This supplement as NOT been approved by FDA and as far as I know is not in large scale human trials. Hopefully that will come as the in vitro (test tube) and animal studies look good. Dr. David Williams, producer of "Alternatives" a newsletter stated that "if MGN-3 were a drug, it would be front-page news." This is currently available in capsule form at health food stores or natural pharmacies. To help get this product tested, contact FDA and ask for human trials. www.fda.gov
ALTERNATIVES newsletter (800)219-8591
Examing the mechanism-Cancer Detection & Prevention
Bill Henderson http://www.Beating-Cancer-Gently.com
Frontiers in Cancer Prevention Research
J Immunology, 2/04
Abstract # 4257
Analysis of Treatment Outcomes in Pancreatic Ca
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.